Attovia Therapeutics, Inc. Common Stock Total Liabilities
Attovia Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Attovia Therapeutics, Inc. Common Stock (ATTO) has total liabilities worth $15.58 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ATTO financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Attovia Therapeutics, Inc. Common Stock (2024–2025)
Total liabilities of Attovia Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how Attovia Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Attovia Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Attovia Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Kinlong Hardware Products Co Ltd
SHE:002791
|
China | CN¥2.69 Billion |
|
Sinopec Oilfield Equipment Corp
SHE:000852
|
China | CN¥7.47 Billion |
|
Fujian Nebula Electronics Co Ltd
SHE:300648
|
China | CN¥1.74 Billion |
|
Vital Energy Inc.
NYSE:VTLE
|
USA | $2.96 Billion |
|
Tong Oil Tools
SHE:300164
|
China | CN¥658.39 Million |
|
Jinxi Axle Co Ltd
SHG:600495
|
China | CN¥760.99 Million |
|
Beijing Join-Cheer Software Co Ltd
SHE:002279
|
China | CN¥839.95 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down Attovia Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Attovia Therapeutics, Inc. Common Stock.
Liquidity & Leverage Metrics
Attovia Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Attovia Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Attovia Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Attovia Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Attovia Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $15.10 Million | +3.53% |
| 2024-12-31 | $14.59 Million | -- |
About Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of… Read more